Switch to
Predicate | Object |
---|---|
rdf:type | |
lifeskim:mentions | |
pubmed:issue |
5
|
pubmed:dateCreated |
1994-2-22
|
pubmed:abstractText |
1. The effects of 1 h intravenous infusions of equimolar amounts (45 nmol min-1 kg-1) of two putative 5-hydroxytryptamine renal prodrugs, 5-hydroxy-L-tryptophan and gamma-L-glutamyl-5-hydroxy-L-tryptophan, were investigated in a randomized, placebo-controlled, cross-over study in nine healthy male subjects. 2. Cumulative urinary 5-hydroxytryptamine excretion over the 3 h observation period rose by about 370-fold after 5-hydroxy-L-tryptophan and 390-fold after gamma-L-glutamyl-5-hydroxy-L-tryptophan when compared with placebo infusion. Urinary 5-hydroxy-L-tryptophan excretion was three times higher after administration of gamma-L-glutamyl-5-hydroxy-L-tryptophan than after 5-hydroxy-L-tryptophan infusion. Urinary 5-hydroxyindole-3-acetic acid excretion after 5-hydroxy-L-tryptophan infusion was significantly greater than that after gamma-L-glutamyl-5-hydroxy-L-tryptophan administration. Urinary dopamine excretion was not affected by either compound when compared with placebo. 3. 5-Hydroxy-L-tryptophan significantly reduced urine flow rate and urinary sodium excretion. gamma-L-Glutamyl-5-hydroxy-L-tryptophan was antinatriuretic but did not affect urine output. These changes occurred without significant alterations in effective renal plasma flow and glomerular filtration rate. 4. Both 5-hydroxy-L-tryptophan and gamma-L-glutamyl-5-hydroxy-L-tryptophan significantly increased plasma aldosterone concentration without a concomitant rise in plasma renin activity.(ABSTRACT TRUNCATED AT 250 WORDS)
|
pubmed:language |
eng
|
pubmed:journal | |
pubmed:citationSubset |
IM
|
pubmed:chemical |
http://linkedlifedata.com/resource/pubmed/chemical/5-Hydroxytryptophan,
http://linkedlifedata.com/resource/pubmed/chemical/Aldosterone,
http://linkedlifedata.com/resource/pubmed/chemical/Prodrugs,
http://linkedlifedata.com/resource/pubmed/chemical/Renin,
http://linkedlifedata.com/resource/pubmed/chemical/Serotonin,
http://linkedlifedata.com/resource/pubmed/chemical/Sodium
|
pubmed:status |
MEDLINE
|
pubmed:month |
Nov
|
pubmed:issn |
0143-5221
|
pubmed:author | |
pubmed:issnType |
Print
|
pubmed:volume |
85
|
pubmed:owner |
NLM
|
pubmed:authorsComplete |
Y
|
pubmed:pagination |
607-14
|
pubmed:dateRevised |
2004-11-17
|
pubmed:meshHeading |
pubmed-meshheading:8287650-5-Hydroxytryptophan,
pubmed-meshheading:8287650-Adult,
pubmed-meshheading:8287650-Aldosterone,
pubmed-meshheading:8287650-Blood Pressure,
pubmed-meshheading:8287650-Dopamine,
pubmed-meshheading:8287650-Glomerular Filtration Rate,
pubmed-meshheading:8287650-Heart Rate,
pubmed-meshheading:8287650-Humans,
pubmed-meshheading:8287650-Kidney,
pubmed-meshheading:8287650-Male,
pubmed-meshheading:8287650-Prodrugs,
pubmed-meshheading:8287650-Renal Blood Flow, Effective,
pubmed-meshheading:8287650-Renin,
pubmed-meshheading:8287650-Serotonin,
pubmed-meshheading:8287650-Sodium,
pubmed-meshheading:8287650-Urination
|
pubmed:year |
1993
|
pubmed:articleTitle |
A comparison of the renal and neuroendocrine effects of two 5-hydroxytryptamine renal prodrugs in normal man.
|
pubmed:affiliation |
Department of Medicine, Royal Infirmary, Edinburgh, U.K.
|
pubmed:publicationType |
Journal Article,
Clinical Trial,
Randomized Controlled Trial
|